Search Results - "LUETKENS, Tim"

Biomarkers for checkpoint inhibition in hematologic malignancies by Atanackovic, Djordje, Luetkens, Tim

“…In the past few years we have seen remarkable paradigm shifts in the treatment of many solid tumors due to the introduction of inhibitors targeting immune…”
Get full text

CD229 CAR T cells eliminate multiple myeloma and tumor propagating cells without fratricide by Radhakrishnan, Sabarinath V., Luetkens, Tim, Scherer, Sandra D., Davis, Patricia, Vander Mause, Erica R., Olson, Michael L., Yousef, Sara, Panse, Jens, Abdiche, Yasmina, Li, K. David, Miles, Rodney R., Matsui, William, Welm, Alana L., Atanackovic, Djordje

“…Multiple myeloma (MM) is a plasma cell malignancy and most patients eventually succumb to the disease. Chimeric antigen receptor (CAR) T cells targeting B-Cell…”
Get full text

Role of immunotherapy in Ewing sarcoma by Morales, Erin, Olson, Michael, Iglesias, Fiorella, Dahiya, Saurabh, Luetkens, Tim, Atanackovic, Djordje

“…Ewing sarcoma (ES) is thought to arise from mesenchymal stem cells and is the second most common bone sarcoma in pediatric patients and young adults. Given the…”
Get full text

The promise of adoptive cellular immunotherapies in hepatocellular carcinoma by Hendrickson, Peter G., Olson, Michael, Luetkens, Tim, Weston, Siani, Han, Tiffany, Atanackovic, Djordje, Fine, Gabriel C.

“…Hepatocellular Carcinoma (HCC) is one of the leading causes of cancer-related mortality worldwide. Current systemic therapies result only in modest benefits…”
Get full text

Novel anti-myeloma immunotherapies targeting the SLAM family of receptors by Radhakrishnan, Sabarinath Venniyil, Bhardwaj, Neelam, Luetkens, Tim, Atanackovic, Djordje

“…Treatment for multiple myeloma (MM) has significantly advanced in the last decade with the introduction of proteasome inhibitors and immunomodulatory…”
Get full text

Immune-mediated facial nerve paralysis in a myeloma patient post B-cell maturation antigen-targeted chimeric antigen receptor T cells by Kathari, Yamini K, Ahmad, Haroon, Kallen, Michael E, Koka, Rima, Omili, Destiny, Iraguha, Thierry, Clement, Jean, Pham, Lily, Khalid, Mazhar, Fan, Xiaoxuan, Gebru, Etse, Lesho, Patricia, Park, Esther, Dishanthan, Nishanthini, Baker, Jillian M, Dietze, Kenneth A, Hankey, Kim G, Badros, Ashraf, Yared, Jean A, Dahiya, Saurabh, Hardy, Nancy M, Kocoglu, Hakan, Luetkens, Tim, Rapoport, Aaron P, Atanackovic, Djordje

Get full text

Simultaneous cytoplasmic and nuclear protein expression of melanoma antigen‐A family and NY‐ESO‐1 cancer‐testis antigens represents an independent marker for poor survival in head and neck cancer by Laban, Simon, Atanackovic, Djordje, Luetkens, Tim, Knecht, Rainald, Busch, Chia‐Jung, Freytag, Marcus, Spagnoli, Giulio, Ritter, Gerd, Hoffmann, Thomas K., Knuth, Alexander, Sauter, Guido, Wilczak, Waldemar, Blessmann, Marco, Borgmann, Kerstin, Muenscher, Adrian, Clauditz, Till S.

“…The prognosis of head and neck squamous cell carcinoma (HNSCC) patients remains poor. The identification of high‐risk subgroups is needed for the development…”
Get full text

Coinhibitory Molecule PD-1 as a Therapeutic Target in the Microenvironment of Multiple Myeloma by Atanackovic, Djordje, Luetkens, Tim, Radhakrishnan, Sabari, Kroger, Nicolaus

“…Patients with Multiple Myeloma suffer from dysregulation of the immune system and new therapeutic options targeting the immune systems such as monoclonal…”
Get more information

Cancer‐testis antigen expression and its epigenetic modulation in acute myeloid leukemia by Atanackovic, Djordje, Luetkens, Tim, Kloth, Benjamin, Fuchs, Gregor, Cao, Yanran, Hildebrandt, York, Meyer, Sabrina, Bartels, Katrin, Reinhard, Henrike, Lajmi, Nesrine, Hegewisch‐Becker, Susanna, Schilling, Georgia, Platzbecker, Uwe, Kobbe, Guido, Schroeder, Thomas, Bokemeyer, Carsten, Kröger, Nicolaus

“…Cancer‐testis antigens (CTA) represent attractive targets for tumor immunotherapy. However, a broad picture of CTA expression in acute myeloid leukemia (AML)…”
Get full text

Chimeric antigen receptor (CAR) T cells for the treatment of a kidney transplant patient with post-transplant lymphoproliferative disorder (PTLD) by Kline, Kathryn, Chen, Wengen, Kallen, Michael E, Koka, Rima, Omili, Destiny, Fan, Xiaoxuan, Iraguha, Thierry, Gebru, Etse, Dishanthan, Nishanthini, Baker, Jillian M, Dietze, Kenneth A, Yared, Jean A, Hankey, Kim, Dahiya, Saurabh, Niederhaus, Silke V, Dunleavy, Kieron, Hardy, Nancy M, Luetkens, Tim, Rapoport, Aaron P, Atanackovic, Djordje

“…Post-transplant lymphoproliferative disorder (PTLD) is a potentially fatal complication following kidney transplantation, and there is a critical and unmet…”
Get full text

Deep dissection of the antiviral immune profile of patients with COVID-19 by Atanackovic, Djordje, Avila, Stephanie V., Lutfi, Forat, de Miguel-Perez, Diego, Fan, Xiaoxuan, Sanchez-Petitto, Gabriela, Vander Mause, Erica, Siglin, Jonathan, Baddley, John, Mannuel, Heather D., Alkhaldi, Hanan, Hankey, Kim G., Lapidus, Rena, Kleinberg, Michael, Rabin, Joseph, Shanholtz, Carl, Rolfo, Christian, Rapoport, Aaron P., Dahiya, Saurabh, Luetkens, Tim

“…In light of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) variants potentially undermining humoral immunity, it is important to understand the…”
Get full text

The cytokine/chemokine pattern in the bone marrow environment of multiple myeloma patients by Cao, Yanran, Luetkens, Tim, Kobold, Sebastian, Hildebrandt, York, Gordic, Maja, Lajmi, Nesrine, Meyer, Sabrina, Bartels, Katrin, Zander, Axel R, Bokemeyer, Carsten, Kröger, Nicolaus, Atanackovic, Djordje

“…Objective The interaction of multiple myeloma (MM) with its bone marrow (BM) microenvironment is important for the homing pattern, survival, and proliferation…”
Get full text

T cell responses against SARS-CoV-2 and its Omicron variant in a patient with B cell lymphoma after multiple doses of a COVID-19 mRNA vaccine by Atanackovic, Djordje, Kreitman, Robert J, Cohen, Jeffrey, Hardy, Nancy M, Omili, Destiny, Iraguha, Thierry, Burbelo, Peter D, Gebru, Etse, Fan, Xiaoxuan, Baddley, John, Luetkens, Tim, Dahiya, Saurabh, Rapoport, Aaron P

“…Anti-SARS-CoV-2 antibodies are crucial for protection from future COVID-19 infections, limiting disease severity, and control of viral transmission. While…”
Get full text

Longitudinal Analysis and Prognostic Effect of Cancer-Testis Antigen Expression in Multiple Myeloma by ATANACKOVIC, Djordje, LUETKENS, Tim, KRÖGER, Nicolaus, HILDEBRANDT, York, ARFSTEN, Julia, BARTELS, Katrin, HORN, Christiane, STAHL, Tanja, YANRAN CAO, ZANDER, Axel R, BOKEMEYER, Carsten

“…Purpose: Reliable data on the persistence of tumor expression of cancer-testis (CT) antigens over time and consequent analyses of the effect of CT antigen…”
Get full text

Humoral immunity against SARS‐CoV‐2 variants including omicron in solid organ transplant recipients after three doses of a COVID‐19 mRNA vaccine by Saharia, Kapil K, Husson, Jennifer S, Niederhaus, Silke V, Iraguha, Thierry, Avila, Stephanie V, Yoo, Youngchae J, Hardy, Nancy M, Fan, Xiaoxuan, Omili, Destiny, Crane, Alice, Carrier, Amber, Xie, Wen Y, Vander Mause, Erica, Hankey, Kim, Bauman, Sherri, Lesho, Patricia, Mannuel, Heather D, Ahuja, Ashish, Mathew, Minu, Avruch, James, Baddley, John, Goloubeva, Olga, Shetty, Kirti, Dahiya, Saurabh, Rapoport, Aaron P, Luetkens, Tim, Atanackovic, Djordje

“…Objectives Solid organ transplant recipients (SOTR) receiving post‐transplant immunosuppression show increased COVID‐19‐related mortality. It is unclear…”
Get full text

Bypassing the cytokine sink: IL-2-independent IL-2 receptor signaling by Luetkens, Tim

Get full text

Cancer-testis antigens MAGE-C1/CT7 and MAGE-A3 promote the survival of multiple myeloma cells by ATANACKOVIC, Djordje, HILDEBRANDT, York, GORDIC, Maja, STAHL, Tanja, ZANDER, Axel R, BOKEMEYER, Carsten, KRÖGER, Nicolaus, JADCZAK, Adam, CAO, Yanran, LUETKENS, Tim, MEYER, Sabrina, KOBOLD, Sebastian, BARTELS, Katrin, PABST, Caroline, LAJMI, Nesrine

“…Multiple myeloma is a life-threatening disease and despite the introduction of stem cell transplantation and novel agents such as thalidomide, lenalidomide,…”
Get full text

5-Azacytidine Promotes an Inhibitory T-Cell Phenotype and Impairs Immune Mediated Antileukemic Activity by Kröger, Nicolaus, Binder, Thomas M. C., Atanackovic, Djordje, Hildebrandt, York, Luetkens, Tim, Badbaran, Anita, Stübig, Thomas, Fehse, Boris

“…Demethylating agent, 5-Azacytidine (5-Aza), has been shown to be active in treatment of myeloid malignancies. 5-Aza enhances anticancer immunity, by increasing…”
Get full text

Elotuzumab as a novel anti-myeloma immunotherapy by Radhakrishnan, Sabarinath Venniyil, Bhardwaj, Neelam, Steinbach, Mary, Weidner, Janet, Luetkens, Tim, Atanackovic, Djordje

“…Treatment of multiple myeloma has undergone significant change in the last decade with the introduction of new immunomodulatory agents, proteasome inhibitors,…”
Get full text

CD229 is expressed on the surface of plasma cells carrying an aberrant phenotype and chemotherapy-resistant precursor cells in multiple myeloma by Yousef, Sara, Kovacsovics-Bankowski, Magdalena, Salama, Mohamed E, Bhardwaj, Neelam, Steinbach, Mary, Langemo, Amanda, Kovacsovics, Tibor, Marvin, James, Binder, Mascha, Panse, Jens, Kröger, Nicolaus, Luetkens, Tim, Atanackovic, Djordje

“…Multiple Myeloma (MM) is a plasma cell (PC) malignancy, which despite significant therapeutic advances, is still considered incurable. This is due to the…”
Get full text